Immunex Message Board - Msg: 14252233

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: manfredhasler who wrote (437)	8/22/2000 1:34:35 AM
From: manfredhasler	of 656

Re: Ken Kam interviewed on IMNX (Marketocracy CEO Interview On RadioWallStreet.com. PHILADELPHIA, Aug 21, 2000 (BUSINESS WIRE) Highlights: - ENBREL got extension in FDA approval 1 month ago which will enlarge the sales potential about 4 times - if congestive heart failure is added, that would double the sales potential one more (then 8 times actual) - as a figure he speaks of more than 2 Billion $/Y sales for ENBREL after some (two?) years. - no mentioning of particular drugs of the rest of the pipeline (beeing in early stage of development) - last weeks price action due to a misconception of investors (or the street): sales of 50 Mill stock by AHP should be absorbed without problem and does not have a diluting effect, albeit might add to the volatility of the stock in near term (offering some buying opportunities according to him). - 20 Mill of new stock sold by IMNX does have a diluting effect. However given the many will be invested in the development of the company and the ensuing enormous increase in sales this should be of no concern to the investor. - his three elephant pics on biotechnology: AMGN/BGEN/IMNX/DNA (interestingly no mentioning of MEDI). He is bullish on Sepracor. Regards, Manfred

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next